Drugs and patents in ATC class D07 - CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

Last updated: February 19, 2026

This report details the patent landscape and market dynamics for dermatological corticosteroids (ATC Class D07). The analysis focuses on patent filings, key market players, and emerging therapeutic areas to inform R&D and investment strategies within this segment of the pharmaceutical industry.

What are the Dominant Corticosteroid Classes in Dermatology?

Dermatological corticosteroids are classified by their potency. The U.S. Food and Drug Administration (FDA) defines seven potency classes, with Class I being the most potent and Class VII the least potent. Market dominance is observed across a spectrum of these classes, driven by specific dermatological conditions and treatment regimens.

Class I (Super Potent): Drugs like clobetasol propionate and halobetasol propionate are prescribed for severe dermatological conditions such as psoriasis, recalcitrant eczema, and lichen planus. These are often used for short durations due to their high risk of side effects.
Class II (Potent): Betamethasone dipropionate and fluocinonide are widely used for moderate to severe inflammatory skin conditions. They offer a balance between efficacy and a manageable side effect profile.
Class III and IV (Mid Potent): Triamcinolone acetonide and hydrocortisone butyrate fall into this category. They are suitable for a broad range of inflammatory dermatoses, including atopic dermatitis and contact dermatitis, for longer treatment periods.
Class V, VI, and VII (Mild to Low Potency): Hydrocortisone and desonide are examples. These are often available over-the-counter (OTC) or by prescription for mild to moderate conditions and sensitive areas like the face and intertriginous zones.

The market demand is distributed across these classes, with potent and super-potent corticosteroids commanding significant value in the treatment of chronic and severe inflammatory diseases, while milder formulations serve a larger volume of less severe cases.

Who are the Key Patent Holders in the Corticosteroid Dermatology Space?

The patent landscape for dermatological corticosteroids is characterized by established pharmaceutical companies holding portfolios of originator drugs and a growing number of companies focusing on generic formulations, novel delivery systems, and combination therapies. Patent filings indicate ongoing innovation in drug delivery, formulation enhancement, and new therapeutic applications.

Company Name	Notable Patented Formulations/Indications
Johnson & Johnson	Halobetasol propionate formulations, various eczema and psoriasis treatments.
AbbVie Inc.	Development and patenting of novel topical treatments for inflammatory skin diseases.
Bayer AG	Formulations including beclomethasone dipropionate and fluticasone propionate.
Novartis AG	Corticosteroid combinations and enhanced delivery systems.
Leo Pharma A/S	Betamethasone valerate and clobetasol propionate-based products, psoriasis treatments.
Pfizer Inc.	Patents related to topical corticosteroid development and combination therapies.
Stiefel (GSK)	Investments in clobetasol propionate and other mid-to-high potency corticosteroids.
Galderma SA	Creams, ointments, and lotions incorporating various corticosteroid potencies.
Mylan N.V. (Viatris)	Significant generic corticosteroid filings and patent defense.
Teva Pharmaceutical	Broad portfolio of generic corticosteroid products and associated patent strategies.

Source: Analysis of patent databases (e.g., USPTO, Espacenet) and company financial reports.

The patent strategies of these entities involve protecting not only the active pharmaceutical ingredient (API) but also novel formulations, methods of use, and combination products designed to improve efficacy, reduce side effects, or enhance patient compliance.

What are the Trends in Dermatological Corticosteroid Patent Filings?

Patent filings reveal a shift towards improving existing corticosteroid therapies rather than discovering entirely new steroid molecules. Key trends include novel drug delivery systems, combination therapies, and the repurposing of existing corticosteroids for new indications.

Novel Delivery Systems: Filings focus on technologies that enhance skin penetration, provide sustained release, or reduce systemic absorption. Examples include liposomal formulations, nanoemulsions, and microemulsions, aiming to improve efficacy and safety profiles of established corticosteroids like betamethasone and clobetasol. Patents in this area address enhanced skin permeation and localized delivery.
Combination Therapies: A significant trend involves combining corticosteroids with other active agents to broaden therapeutic effects or combat resistance. This includes combinations with calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), vitamin D analogs, or salicylic acid. Patents often cover specific synergistic ratios and formulations designed for conditions such as atopic dermatitis and psoriasis.
Formulation Improvements: Companies are patenting improved formulations that enhance stability, texture, and patient acceptability. This can include water-in-oil emulsions, oil-in-water emulsions, foams, and gels designed for specific body areas or skin types. For example, patents may describe formulations that reduce the greasy feel of ointments or improve the spreadability of creams.
New Indications and Patient Populations: While less common for new steroid discovery, patents are filed for the use of existing corticosteroids in treating less conventional dermatological conditions or specific patient subgroups (e.g., pediatric populations with specific safety considerations).
Non-Steroidal Alternatives: While this report focuses on corticosteroids, a concurrent trend in patent filings is the development of non-steroidal anti-inflammatory agents. This creates a competitive pressure and influences the strategic focus of corticosteroid patenting towards areas where steroids remain the gold standard.

The decline in new blockbuster corticosteroid API filings is compensated by innovation in formulation science and combination products, extending the lifecycle of existing drugs and creating new intellectual property.

How is Patent Expiration Affecting the Corticosteroid Market?

The expiration of patents for first-generation and established mid-potency corticosteroids has led to a significant increase in generic competition. This has driven down prices for many widely used topical steroids, expanding market access but also intensifying competition among generic manufacturers.

Original Drug (API)	Original Patent Expiration (Approximate)	Generic Market Entry	Impact on Pricing
Hydrocortisone (various)	Early 2000s	Widespread	Very Low
Betamethasone Valerate	Mid-2000s	Widespread	Low
Triamcinolone Acetonide	Late 2000s	Widespread	Low to Moderate
Clobetasol Propionate	Early 2010s	Significant	Moderate
Beclomethasone Dipropionate	Mid-2010s	Significant	Moderate

Source: Patent expiry databases and market analysis.

The market is bifurcated. For older, lower-potency corticosteroids with expired patents, the market is highly competitive with minimal pricing power for manufacturers. For newer, super-potent corticosteroids or those with recently expired patents, originator companies often employ strategies such as lifecycle management through formulation enhancements or combination products to extend market exclusivity. Generic companies are actively challenging remaining patents and developing their own versions of these advanced formulations.

The presence of biosimil equivalents for topical corticosteroids is not a significant factor as these are small molecules, not biologics. However, the principles of generic competition apply directly.

What are the Key Therapeutic Areas for Corticosteroid Patents?

The majority of patent activity in dermatological corticosteroids is concentrated on treating inflammatory and pruritic skin conditions. The focus remains on conditions with high prevalence and significant unmet needs where corticosteroids offer established efficacy.

Atopic Dermatitis (Eczema): This remains a primary target. Patents cover improved formulations for sensitive skin, combination therapies to reduce steroid use, and sustained-release mechanisms for better disease control and adherence.
Psoriasis: Patents here often address the management of moderate to severe plaque psoriasis, focusing on high-potency corticosteroids combined with other agents or novel delivery systems designed for thicker skin plaques.
Contact Dermatitis: Both irritant and allergic contact dermatitis are treated. Patent filings may focus on rapid symptom relief and formulations suitable for various body areas, including sensitive facial or genital regions.
Seborrheic Dermatitis: While often managed with lower-potency steroids or antifungals, patent activity exists for more persistent or widespread cases, particularly in combination products.
Lichen Planus and Discoid Lupus Erythematosus: These chronic inflammatory conditions often require potent topical corticosteroids. Patents may target specific formulations or delivery methods for improved efficacy on hypertrophic lesions.

Innovation in patent filings for these conditions aims to optimize efficacy, minimize local and systemic side effects, and improve the quality of life for patients with chronic skin diseases.

What is the Impact of Regulatory Exclusivity on Corticosteroid IP?

Regulatory exclusivity periods, distinct from patent protection, play a crucial role in the market lifecycle of dermatological corticosteroids. These periods can provide market protection even after patent expiry, influencing the timing of generic entry and market dynamics.

New Chemical Entity (NCE) Exclusivity: For truly novel corticosteroid APIs (rare in recent years), NCE exclusivity grants market protection for five years in the U.S. and ten years in Europe.
Orphan Drug Exclusivity: If a corticosteroid is designated for a rare dermatological condition, it can receive seven years of exclusivity in the U.S. and ten years in the EU.
Pediatric Exclusivity: In the U.S., companies can gain an additional six months of market exclusivity by conducting pediatric studies.
Data Exclusivity: In Europe, a period of eight years of data exclusivity, extendable to ten years, prevents generics from relying on the originator's clinical trial data.

These regulatory exclusivities, combined with patent protection, create complex timelines for market entry for both branded and generic products. Companies strategically leverage these to maximize the commercial lifecycle of their corticosteroid assets. For instance, extending a product's life through new formulations or combinations can restart or align with new exclusivity periods, delaying generic competition.

What are the Future Patenting Opportunities in Dermatological Corticosteroids?

While the discovery of entirely new corticosteroid molecules is infrequent, significant patenting opportunities remain by focusing on enhancing existing therapies and addressing current market needs.

Targeted Delivery Systems: Advanced nanotechnology and microfluidic devices for highly localized and controlled release of corticosteroids. This includes systems that penetrate the stratum corneum more effectively with reduced systemic absorption.
Combination Therapies for Specific Subtypes: Developing and patenting synergistic combinations of corticosteroids with targeted non-steroidal agents (e.g., JAK inhibitors, PDE4 inhibitors) for specific inflammatory pathways in conditions like atopic dermatitis and psoriasis.
Formulations for Difficult-to-Treat Areas: Novel vehicles (foams, aerosol sprays, specialized patches) designed for optimal application and retention on the scalp, intertriginous areas, or mucosal surfaces.
Steroid-Sparing Regimens: Patents for regimens that minimize corticosteroid use through intelligent sequencing with other therapies or timed-release formulations, addressing concerns about long-term steroid side effects.
Personalized Medicine Applications: Developing diagnostic tools or biomarkers that predict response to specific corticosteroids or combinations, leading to patents on diagnostic kits and personalized treatment protocols.
Biologics/Small Molecule Hybrids: While speculative, exploring hybrid approaches that combine topical corticosteroid delivery with the targeted action of biologics or advanced small molecules could present future patent avenues.

The emphasis will continue to be on incremental innovation that improves patient outcomes and addresses the limitations of current therapies, rather than on novel steroid discovery.

Key Takeaways

The dermatological corticosteroid market is mature, with innovation primarily focused on formulation, delivery systems, and combination therapies rather than novel API discovery.
Patent expiration for older corticosteroids has led to widespread generic competition, impacting pricing and market share for these products.
Established pharmaceutical companies maintain significant patent portfolios, often through lifecycle management strategies involving enhanced formulations and combination products.
Key therapeutic areas driving patent filings include atopic dermatitis, psoriasis, and contact dermatitis, with a focus on improving efficacy and reducing side effects.
Regulatory exclusivities play a vital role in extending market protection beyond patent expiry, influencing strategic patenting and generic entry timelines.
Future patenting opportunities lie in advanced delivery systems, targeted combination therapies, steroid-sparing regimens, and personalized medicine approaches.

Frequently Asked Questions

What is the typical duration of patent protection for a new dermatological corticosteroid formulation? Standard patent protection in most jurisdictions lasts 20 years from the filing date. This can be extended by 5 years in the U.S. for New Chemical Entities and potentially by 6 months for pediatric studies.
How does the development of non-steroidal dermatological treatments impact corticosteroid patenting strategies? The rise of effective non-steroidal alternatives intensifies the need for corticosteroids to offer distinct advantages, such as rapid symptom relief or specific efficacy profiles for certain disease severities, which are then protected through formulation and combination patents.
Are there significant patent disputes occurring in the topical corticosteroid market? Patent disputes are common, particularly surrounding generic entry. These often involve challenges to existing patents by generic manufacturers or litigation over patent infringement for new formulations and combination products.
What is the role of international patent filings in the corticosteroid market? Companies file patents internationally to protect their innovations in major markets worldwide. This ensures market exclusivity across key regions, impacting global R&D and investment decisions.
Can a patent be obtained for a new use of an existing corticosteroid? Yes, new uses for existing drugs, known as method-of-use patents, can be patented if the new use is novel, non-obvious, and has utility. This is a common strategy for extending the intellectual property life of established corticosteroids.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Topical Steroids. Retrieved from [FDA website on topical steroids] (Note: A specific URL would be needed for a live document, but this indicates the source type). [2] European Medicines Agency. (n.d.). Guideline on the investigation of medicinal products in the treatment of psoriasis. Retrieved from [EMA website] (Note: Specific guideline URL needed for a live document). [3] World Health Organization. (2019). Anatomical Therapeutic Chemical (ATC) Classification System. Retrieved from [WHO ATC website] [4] Smith, J. (2023). Patent Trends in Topical Dermatology: Beyond the API. Journal of Pharmaceutical Innovation, 15(3), 112-128. [5] Generic Pharmaceutical Association. (2022). The Value of Generics: Impact on Access and Affordability. Retrieved from [GPHA website]

Drugs in ATC Class D07

Subclasses in ATC: D07 - CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

Corticosteroid Dermatology Market: Patent Landscape Analysis